朗迪集團(603726.SH):擬行使優先配售權參與認購甬矽電子可轉債
格隆匯6月24日丨朗迪集團(603726.SH)公佈,公司參股公司甬矽電子(寧波)股份有限公司(證券代碼:688362,證券簡稱:甬矽電子)向不特定對象發行規模不超過人民幣116,500.00萬元的可轉換公司債券(簡稱:“甬矽電子可轉債”)。截至目前,公司持有甬矽電子股份3,100萬股,持股比例7.57%,享有甬矽電子本次發行可轉債的優先配售權。公司擬行使優先配售權參與認購甬矽電子可轉債。公司本次計劃參與認購甬矽電子可轉債的投資本金不超過8,924.90萬元人民幣(含本數),佔公司2024年度經審計淨資產的6.91%,佔公司2025年第一季度未經審計淨資產的6.71%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.